Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

2005457 citationsJournal Articlehybrid Open Access

Authors

Philip A. Philip · Mayo Clinic in Arizona

Michelle R. Mahoney · Johns Hopkins University

Cristine Allmer · The Barbara Ann Karmanos Cancer Institute

James P. Thomas · Johns Hopkins University

Henry C. Pitot · Wayne State University

George Kim · Mayo Clinic in Arizona

Ross C. Donehower

Abstract

Results of this trial suggest a benefit for EGFR/HER1 blockade with erlotinib in patients with HCC manifested by disease control. Additional studies with erlotinib as a single agent or in combination with other agents are warranted.

Topics & Keywords

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 23, Issue 27, pp. 6657-6663

DOI: 10.1200/jco.2005.14.696

Field-Weighted Citation Impact: 25.12